MYCN amplifications [4, 5], telomerase activation by genomic rearrangements [6, 7], ATRX loss-of-function mutations or deletions [8–10] and germline or somatically acquired activating ALK mutations [11–14] define patient subgroups with highly aggressive and frequently therapy-resistant neuroblastomas. The gene discussed is MYCN; the disease is neuroblastoma.